Compare CCS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCS | IMNM |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2014 | 2020 |
| Metric | CCS | IMNM |
|---|---|---|
| Price | $60.30 | $19.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $70.50 | $26.89 |
| AVG Volume (30 Days) | 240.3K | ★ 1.2M |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.93 | N/A |
| Revenue | ★ $4,157,669,000.00 | $9,679,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.74 | N/A |
| P/E Ratio | $8.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $50.42 | $5.15 |
| 52 Week High | $88.41 | $20.46 |
| Indicator | CCS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 60.95 |
| Support Level | $63.69 | $16.81 |
| Resistance Level | $67.10 | $20.46 |
| Average True Range (ATR) | 2.10 | 1.20 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 38.97 | 72.74 |
Century Communities Inc is engaged in the development, design, construction, marketing, and selling of single-family attached and detached homes. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its sales representatives and independent real estate brokers. The company generates the majority of its revenue from the Mountain segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.